Stocks Health care BJDX
NASDAQ · Health careBluejay Diagnostics, Inc. (BJDX)
It posted a net loss of $7.3M. In fiscal 2025 capital spending exceeded operating cash flow by $6.2M. At June 30, 2026 it held $9.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Bluejay Diagnostics, Inc.
- Net worth
- Bluejay Diagnostics, Inc. has a market value (market cap) of $12.6M at the latest share price, and shareholders' equity of $9.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $249K, with a net loss of $9.3M.
- Cash flow
- In fiscal 2025 operations used $6.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Bluejay Diagnostics, Inc. does
Bluejay Diagnostics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker BJDX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$6.8M | -$15.25 | -$6.2M |
| 2024 | n/a | -$7.7M | -$456.75 | -$8.1M |
| 2023 | n/a | -$10M | -$14,525.60 | -$9M |
| 2022 | $249K | -$9.3M | -$14,749.57 | -$8.9M |
| 2021 | n/a | -$3.5M | -$13,146.35 | -$4.4M |
| 2021 | n/a | -$1.2M | -$11,863.78 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Bluejay Diagnostics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- September 8, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 13, 2026
- August 12, 2026
- August 12, 2026
- July 22, 2026
- June 17, 2026
- June 9, 2026
Insider trades
What the people running Bluejay Diagnostics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 17, 2026 | Dey IndranilPresident and CEO, Director | Received as pay | 28,000 | - |
| July 10, 2026 | Hrt Financial LP10% owner | Sold | 34,938 | $48.9K |
| July 9, 2026 | Hrt Financial LP10% owner | Bought | 64,047 | $96.7K |
| March 14, 2026 | Dey SvetlanaDirector | Bought | 12,500 | $25K |
| March 14, 2026 | Zeidman Fred SDirector | Bought | 12,500 | $25K |
| March 14, 2026 | Chase Donald RDirector | Bought | 12,500 | $25K |
| March 14, 2026 | Dey IndranilPresident and CEO, Director | Bought | 12,500 | $25K |
| March 14, 2026 | Wurth Douglas ClarkDirector | Bought | 12,500 | $25K |
Who owns BJDX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Armistice Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Ayrton Capital LLC13G, passive with 2 related filers | 9.99% | August 13, 2026 |
| Mitchell P. Kopin13G, passive with 2 related filers | 9.99% | June 5, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 182,711 shares in total, about $511.6K at the last price.
| Holder | Shares |
|---|---|
| Hrt Financial LP10% owner | 92,055 |
| Dey IndranilPresident and CEO, Director | 40,522 |
| Wurth Douglas ClarkDirector | 12,608 |
| Chase Donald RDirector | 12,525 |
| Dey SvetlanaDirector | 12,501 |
| Zeidman Fred SDirector | 12,500 |
Questions about BJDX
What does Bluejay Diagnostics, Inc. do?
Bluejay Diagnostics, Inc. is a company in the Health care sector, listed on NASDAQ as BJDX. Its shares trade on NASDAQ under the ticker BJDX.
What is Bluejay Diagnostics, Inc.'s net worth?
Bluejay Diagnostics, Inc. has a market value (market cap) of $12.6M at the latest share price, and shareholders' equity of $9.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bluejay Diagnostics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $7.3M.
When did Bluejay Diagnostics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 6, 2026.
Similar companies
Compare BJDX with
Follow BJDX
Get an email when Bluejay Diagnostics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bluejay Diagnostics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.